Cheng Cheng

Dr. Cheng Cheng

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2025 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
YZYingying Zhang
Yingying Zhang
WDWeiwei Du
Weiwei Du
TKTing Kong
Ting Kong
THTianfeng Hua
Tianfeng Hua
HMHonghao Ma
Honghao Ma
CCCheng Cheng
Cheng Cheng
Targeted temperature management (TTM) is a vital intervention for cardiac arrest survivors to mitigate post-resuscitation myocardial dysfunction (PRMD). However, the optimal temperature for TTM remains a topic of debate. This study investigates the effects of TTM at different temperatures and explores the underlying mechanisms using in vivo and in vitro models of myocardial ischemia/reperfusion (I/R) injury following cardiac arrest (CA) and cardiopulmonary resuscitation (CPR). We found that TTM at 33 °C significantly improved post-resuscitation hemodynamics and myocardial function, reducing both myocardial and mitochondrial damage in the rat model of CA/CPR. Additionally, Deferoxamin (DFO), as an iron chelating agent, also demonstrated protective effects against PRMD. Both in vitro and in vivo experiments confirmed that hypothermia at 33 °C and DFO mitigated mitochondrial damage, oxidative stress, lipid peroxidation, and iron overload, while suppressing ferritinophagy and ferroptosis. Furthermore, TTM at 33 °C and DFO facilitated the nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2), with Nrf2 activation leading to inhibited ferritinophagy and enhanced iron export. Our findings indicate that TTM at 33° C, as opposed to 36° C, significantly alleviates PRMD and reduced myocardial damage by inhibiting ferroptosis. Theses protective effects are associated with Nrf2 activation and modulation of iron homeostasis. Moreover, DFO not only suppressed ferroptosis through its iron chelation properties but also by activating the Nrf2 axis.

8 August 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
CCCheng Cheng
Cheng Cheng
BXBanglong Xu
Banglong Xu
JSJianlong Sheng
Jianlong Sheng
ZHZheng Huang
Zheng Huang
FHFei He
Fei He
XWXiaochen Wang
Xiaochen Wang
Objectives. To investigate the procedural efficiency, efficacy, and safety of high-power, short-term radiofrequency ablation delivered by the SmartTouch Surround Flow (STSF) catheter for paroxysmal atrial fibrillation (AF). Methods. We retrospectively analyzed a total of 72 patients who were admitted with paroxysmal AF, and who underwent radiofrequency catheter ablation (RFCA) for the first time. Of these patients, 36 cases underwent low-power, long-duration (LPLD, (30–35 W/20–40 s) pulmonary vein isolation (PVI) delivered by an SmartTouch (ST) catheter (control group), and the other 36 cases underwent high-power, short-duration (HPSD, (45–50 W/10–20 s) PVI delivered by a STSF catheter (study group). The baseline data, duration of PVI, procedural time, fluoroscopy time, the rate of first-pass isolation, irrigation perfusion, eschar and steam pop occurrences, intraoperative complications, and the rate of stable sinus rhythm maintenance following a blanking period of three months were analyzed between the two groups. Results. The isolation time of bilateral PVI and procedural time in the study group were markedly less than in controls ( ). The rate of first-pass isolation in the study group was significantly higher than in the control group (95.8% vs. 84.7%, ), while the fluid perfusion in the study group was approximately 20% less than that in the control group (767 ± 171 vs. 966 ± 227 ml, ). We observed no severe complications in any patients. The rate of freedom from AF recurrences following a blanking period of three months showed a tendency to be higher than in controls (93.9% vs. 87.1%, ). Conclusions. The HPSD strategy delivered by the STSF catheter was superior to conventional LPLD ablation through the ST catheter with respect to efficiency, acute procedural effectiveness, short-term safety, and the risk of heart failure in patients with paroxysmal AF.

11 November 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
LCLei Chen
Lei Chen
LLLi-Li Liu
Li-Li Liu
ZZZun-Jiang Zhao
Zun-Jiang Zhao
DLDa-Lun Lv
Da-Lun Lv
CCCheng Cheng
Cheng Cheng
HSHui-Juan Shu
Hui-Juan Shu

15 December 2023 in Medicine
Verified
Journal Article
Open access
QMQiang Mpe Ma
Qiang Mpe Ma
CCCheng Cheng
Cheng Cheng
YCYuenan Mm Chen
Yuenan Mm Chen
QWQianya Bd Wang
Qianya Bd Wang
BLbaozhu li
baozhu li
PWPing Wang
Ping Wang
The study aims to explore the current status of hypertension control and its predictors in patients with hypertension in China and provide evidence for preventing and controlling hypertension. A questionnaire survey was conducted among 300 hypertensive patients who visited the Second Affiliated Hospital of Anhui Medical University from February 20, 2023 to March 11, 2023. The patients were divided into a well-controlled group and an untargeted-control group according to their hypertension control status. A total of 294 subjects, including 83 in the well-controlled group and 211 in the untargeted-control group, were included in the analysis. Multivariate logistic regression analysis showed that hypertensive patients with high BMI and family history of hypertension were risk factors for hypertension control. Married status was a protective factor for hypertension control. SVM optimized the model with γ = 0.001 and a penalty factor of C = 0.001. The prediction accuracy of the final model was 80.9%. The findings indicated that BMI, family history of hypertension, and marital status were independent predictors of blood pressure control. Further studies are warranted to illustrate potential mechanisms for improving hypertensive patients’ blood pressure control.

1 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
XSXiaodong Shang
Xiaodong Shang
HZHengwei Zhang
Hengwei Zhang
JHJinxiao Hou
Jinxiao Hou
JOJohn Oruongo
John Oruongo
CCCheng Cheng
Cheng Cheng
QJQian Jun
Qian Jun
Background Current physical activity (PA) guidelines emphasize weekly volume, but how activity is distributed across active days may also influence cardiovascular health (CVH). We examined whether these weekly accumulation patterns are associated with CVH. Methods We conducted a cross-sectional analysis of adults aged 20–64 years without established cardiovascular disease (CVD) in the National Health and Nutrition Examination Survey (2007- March 2020). PA was self-reported and categorized as inactive (< 30 min/week), low-volume (30–89 min/week), intermediate-volume (90–149 min/week), or guideline-adherent (≥150 min/week). Within low- and intermediate-volume groups, participants were further classified as distributed (<30 or < 45 minutes on active days) or concentrated (≥30 or ≥ 45 minutes on active days). CVH was assessed using the American Heart Association’s Life’s Essential 8 (LE8). Associations were examined with LOESS smoothing and propensity score matching. Results Among 9,851 participants, 48.7% were inactive and only 33.2% met guideline PA levels. In the low-volume group, individuals with concentrated patterns (≥30 minutes on active days) had significantly better blood pressure scores compared with those with distributed patterns (<30 minutes; p=0.045). In the intermediate-volume group, the concentrated patterns (≥45 minutes on active days) were associated with more favorable glycemic (p<0.001) and lipid profiles (p=0.013), independent of total weekly volume. Dose-response analyses identified 30–45 minutes on active days as the optimal range for cardiometabolic benefits. Conclusion Weekly accumulation patterns independently influenced CVH among adults below guideline PA levels. Concentrating ≥ 30-45 minutes on active days was associated with better blood pressure, glucose, and lipid profiles without increasing weekly volume. These findings highlight active-day duration as a novel, modifiable, and time-efficient behavioral target for cardiovascular prevention. What is New? This is the first study to show that the way activity is structured across active days— whether spread in shorter bouts or sustain longer sessions —independently affects cardiovascular health. Accumulating ≥30–45 minutes of activity on active days was linked to better blood pressure, glucose, and lipid profiles compared with shorter distributed durations, even without increasing total weekly minutes. What are the Clinical Implications? Clinicians can shift counseling from simply "do more" toward "do smarter": how patients distribute their activity matters for cardiovascular health. Recommending ≥30–45 minutes of sustained activity on active days offers an efficient, achievable strategy that benefits patients who cannot meet weekly guideline totals. Framing active-day duration as a time-efficient and equitable behavioral target provides a practical pathway for personalized cardiovascular prevention.